Form 8-K Dogwood Therapeutics, For: Jan 20
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- Wall St futures slip as chip stocks drag; Netflix tumbles
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Goldman sees central bank demand providing a floor for gold prices
- Nike out of World Cup contention as Adidas-outfitted teams head to final
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
- FDA approves Merck's Lipfendra as first oral PCSK9 inhibitor
- Intuitive Surgical (ISRG) Tops Q2 EPS by 29c, Beats on Revenue
Dogwood Therapeutics provides 2025 progress update
January 20, 2026 8:38 AM ESTDogwood Therapeutics Inc. (NASDAQ: DWTX) issued a corporate update detailing progress in its development of non-opioid medicines for pain and neuropathy treatment.
The biotechnology company reported recruiting over 100 patients for its Halneuron Phase 2b Chemotherapy Induced Pain study, completing an interim analysis to determine final study sample size and analysis... More
